Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

Launched by UNIVERSITY OF ZURICH · May 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for HIV using a combination of two medications called Cabotegravir and Rilpivirine, given as a long-acting injection. The goal is to understand how well this treatment works for people in Switzerland who are starting this regimen, how well they stick to the treatment guidelines, and what factors might lead to treatment failures. Researchers will look at various aspects like the participants' health and lifestyle to see how these might affect the success of the treatment.

To be eligible for this study, participants must be part of the Swiss HIV Cohort Study and be starting the Cabotegravir and Rilpivirine treatment or currently on standard oral HIV medications. Participants can expect to be part of a large group of people receiving care across different medical centers, and their experiences will help improve treatment options for HIV. The trial is currently recruiting participants, and everyone aged 16 and older, regardless of gender, is welcome to join as long as they meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant in the SHCS
• • All SHCS participants initiating the CAB+RPV LA regimen
• • All SHCS participants on SOC oral regimen
• Exclusion Criteria:
• • Not participating in the SHCS